52
Participants
Start Date
October 31, 2010
Primary Completion Date
December 31, 2013
Study Completion Date
January 31, 2014
CMV-specific T-cells, single infusion following single positive CMV PCR result
"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
QEH Birmingham Hospital, Birmingham
Bristol Royal Hospital, Bristol
Kings College Hospital, London
Royal Free Hospital, London
Manchester Royal Infirmary, Manchester
The Christie, Manchester
Nottingham University Hospital - City Campus, Nottingham
Churchill Hospital, Oxford
University College London Hospital, London
Lead Sponsor
Leukaemia Lymphoma Research
OTHER
National Health Service, Blood and Transplant
UNKNOWN
University of Birmingham
OTHER
Cell Medica Ltd
INDUSTRY